Moderate-dose Hypofractionated Intensity-modulated Radiotherapy

RADIATION2 trials

Sponsors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions

Hepatocellular CarcinomaPembrolizumabRadiotherapyTislelizumabTumor Thrombosis

Phase 2

Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis

CompletedNCT06233981

Cancer Institute and Hospital, Chinese Academy of Medical SciencesHepatocellular Carcinoma, Radiotherapy, Tislelizumab +1

Start: 2024-01-25End: 2026-01-01Updated: 2026-04-17

Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis

RecruitingNCT06389422

Cancer Institute and Hospital, Chinese Academy of Medical SciencesHepatocellular Carcinoma, Pembrolizumab, Radiotherapy +1

Start: 2024-05-01End: 2027-04-30Target: 30Updated: 2024-04-29